What Is the Future of the Human Rabies Immunoglobulin Market? 2025–2032 Outlook According to a newly published market research report by 24LifeSciences, global Human Rabies Immunoglobulin (IM) market was valued at USD 299 million in 2024 and is projected to reach USD 378 million by 2032, growing at a compound annual growth rate (CAGR) of 3.5% during the forecast period. Human Rabies Immunoglobulin (IM) is a critical passive immunization biologic derived from human plasma, containing concentrated antibodies that neutralize the rabies virus immediately after exposure. It is an essential component of the World Health Organization-recommended post-exposure prophylaxis (PEP) regimen administered for Category III exposures such as deep bites, scratches, or mucous membrane contact with saliva from suspected rabid animals. As a life-saving intervention, its established efficacy in providing immediate passive immunity continues to underpin its global importance in public health and emergency medicine protocols. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/1786/human-rabies-immunoglobulin-im-market

BCG Vaccine Market to Grow at 3.3% CAGR Through 2032 According to a newly published market research report by 24LifeSciences, global Bacille Calmette-Guerin vaccine market was valued at USD 73.4 million in 2024 and is projected to reach USD 91.7 million by 2031, growing at a compound annual growth rate (CAGR) of 3.3% during the forecast period of 2025-2031. Bacille Calmette-Gurin (BCG) vaccine, a live-attenuated strain derived from Mycobacterium bovis, remains the world's most widely administered vaccine for tuberculosis prevention and stands as a cornerstone in global immunization programs. Its primary role involves protecting infants and young children in regions with high TB prevalence from severe forms of the disease, including military TB and TB meningitis. While its efficacy against pulmonary TB in adults shows limitations, its established protective benefits for pediatric populations ensure its continued relevance in public health strategies worldwide. Beyond TB prevention, the vaccine has gained significant therapeutic importance in oncology, particularly for the treatment of non-muscle-invasive bladder cancer, representing a vital secondary application that diversifies its market value. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/3756/bacille-calmette-guerin-vaccine-market

Top 10 Companies Leading the Swine Autogenous Vaccines Market Growth According to a newly published market research report by 24LifeSciences, global swine autogenous vaccines market was valued at USD 396 million in 2024 and is projected to reach USD 569 million by 2031, growing at a compound annual growth rate (CAGR) of 6.1% during the forecast period 2025–2031. Swine autogenous vaccines, representing a specialized segment within veterinary biologics, are custom-developed immunizations created using pathogens isolated from specific pig herds. These farm-specific vaccines address the critical limitations of conventional commercial vaccines by providing precisely targeted protection against unique bacterial and viral strains circulating within individual production systems. Their growing adoption reflects a fundamental shift toward precision livestock health management, where prevention is prioritized over treatment in modern swine operations. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/5173/swine-autogenous-vaccines-market